3.3. Initial Participant Characteristics in the Clinical Study
BLOOD
A total of 100 healthy adults were asked to participate in the study, and one participant withdrew from the study due to personal reasons. Blood samples collected from the participants at the screen visit were used for pDC surface marker CD86 and HLA-DR analysis and safety parameter testing. The results of surface marker activity on pDCs were considered a priority factor for randomization. One participant withdrew from the trial due to personal vaccination plan. The remaining 99 participants were randomized into two groups receiving either live BB536 (1 × 10